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Mitochondrial Encephalomyopathy and Complex III Deficiency Associated
with a Stop-Codon Mutation in the Cytochrome b Gene
J. Andrew Keightley,1,* Roberto Anitori,1,† Miriam D. Burton,1,‡ Franklin Quan,1,§
Neil R. M. Buist,1,2 and Nancy G. Kennaway1
Departments of 1Molecular and Medical Genetics and 2Pediatrics, Oregon Health Sciences University, Portland
We have reinvestigated a young woman, originally reported by us in 1983, who presented with exercise intolerance
and lactic acidosis associated with severe deficiency of complex III and who responded to therapy with menadione
and ascorbate. Gradually, she developed symptoms of a mitochondrial encephalomyopathy. Immunocytochemistry
of serial sections of muscle showed a mosaic of fibers that reacted poorly with antibodies to subunits of complex
III but reacted normally with antibodies to subunits of complexes I, II, or IV, suggesting a mutation of mtDNA.
These findings demonstrate the diagnostic value of immunocytochemistry in identifying specific respiratory-chain
deficiencies and, potentially, distinguishing between nuclear- or mtDNA-encoded defects. Sequence analysis revealed
a stop-codon mutation (G15242A) in the mtDNA-encoded cytochrome b gene, resulting in loss of the last 215
amino acids of cytochrome b. PCR-RFLP analysis indicated that the G15242A mutation was heteroplasmic and
was present in a high percentage (87%) of affected tissue (skeletal muscle) and a low percentage (0.7%) of unaffected
tissue (blood) but was not detected in controls. Analysis of microdissected muscle fibers showed a significant
correlation between the immunoreactivity toward the Rieske protein of complex III and the percentage of mutant
mtDNA: immunopositive fibers had a median value of 33% of the G15242A mutation, whereas immunonegative,
ragged-red fibers had a median value of 89%, indicating that the stop-codon mutation was pathogenic in this
patient. The G15242A mutation was also present in several other tissues, including hair roots, indicating that it
must have arisen either very early in embryogenesis, before separation of the primary germ layers, or in the maternal
germ line. The findings in this patient are contrasted with other recently described patients who have mutations
in the cytochrome b gene.
Introduction
The mitochondrial myopathies and encephalomyopa-
thies (MIM 251900) are an increasingly recognized and
diverse group of disorders of mitochondrial function
that are frequently associated with defects of the res-
piratory chain (DiMauro and Bonilla 1997; DiMauro et
al. 1998). The diversity of these disorders reflects not
only the complexity of the respiratory chain itself, made
up of 180 individual proteins that are organized into
five major complexes (I–V), but also the unique prop-
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erties of mtDNA, which encodes 13 of these polypep-
tides: 7 (ND1–6 and 4L) in complex I (NADH:ubiqui-
none oxidoreductase); 1 (cytochrome b) in complex III
(ubiquinol:cytochrome c reductase); 3 (COX I–III) in
complex IV (cytochrome c oxidase); and 2 (A6 and A8)
in complex V (ATP synthase). Because of the small size
and known sequence of human mtDNA (Anderson et
al. 1981), many mutations have now been recognized
(Chinnery and Turnbull 1999). These disorders are clin-
ically and biochemically heterogeneous, most often be-
ing associated with deficient activity of complex I, com-
plex IV, or both. Disorders of complex III are relatively
rare. Because of the overlap of clinical findings and fre-
quent lack of correlation among the biochemical, his-
tochemical, and molecular data, these disorders are best
classified on the basis of the pathogenic mtDNA mu-
tation. Hundreds of large-scale rearrangements of
mtDNA (deletions and/or duplications) and 150 path-
ogenic point mutations in tRNA genes have been rec-
ognized (Chinnery et al. 1999; Wallace 1999). Patho-
genic mutations in the rRNA or protein-coding genes
are less frequent. Most disorders of mtDNA are heter-
oplasmic, meaning that both normal and mutant
mtDNA species are present. They are frequently asso-
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ciated with so-called ragged red fibers (RRFs) seen on
muscle biopsies, reflecting the proliferation of mutant
mitochondria in energy-deficient fibers. In contrast to
the major rearrangements of mtDNA, which are most
often associated with progressive external ophthalmo-
plegia or Kearns-Sayre syndrome (MIM 530000) and
which are almost always sporadic, many mutations in
the tRNA, rRNA, or protein-coding genes are inherited
from the mother, reflecting the maternal inheritance of
the mitochondrial genome. Well-known examples are
the A3243G mutation in the mitochondrial tRNALeu(UUR)
gene, which is associated with mitochondrial encepha-
lomyopathy, lactic acidosis, and strokelike episodes
(MELAS [MIM 540000]); the A8344G mutation in the
tRNALys gene, which is associated with myoclonic epi-
lepsy with RRFs (MERRF [MIM 545000]); and the
G11778A mutation in ND4 (subunit 4 of complex I),
which is associated with Lebers hereditary optic neu-
ropathy (LHON [MIM 535000]).
Until recently, relatively few patients with isolated
complex III deficiency (MIM 124000) had been re-
ported, and only in one of these had a mutation in the
cytochrome b gene (MIM 516020) been shown to be
pathogenic (Dumoulin et al. 1996). In 1998, we pub-
lished a preliminary abstract (Kennaway et al. 1998)
documenting a stop-codon mutation in the cytochrome
b gene in muscle from a patient with severe exercise
intolerance and lactic acidosis, associated with complex
III deficiency, who responded to menadione and ascor-
bate (Darley-Usmar et al. 1983; Kennaway et al. 1984;
Argov et al. 1986). Since then, 12 additional pathogenic
mutations in the cytochrome b gene have been described
(Andreu et al. 1998, 1999a, 1999c, 2000; De Coo et
al. 1999; Legros et al. 1999; Pulkes et al. 1999; Valnot
et al. 1999). Interestingly, most of these patients have
presented with the predominant feature of severe ex-
ercise intolerance, sometimes including muscle weak-
ness and/or myoglobinuria. Two had hypertrophic car-
diomyopathy. We now present the characterization of
the cytochrome b mutation in our patient, provide an
update of her disease progression over the past 15 years,
and contrast our findings regarding her with those of
other reported patients.
Patient and Methods
Patient
The proband is a 34-year-old woman who was first
seen by us at age 17 years. She had a history of pro-
gressive exercise intolerance and lactic acidosis starting
at age ∼9 years. Muscle biopsy revealed many RRFs and
severe deficiency of complex III activity (5% of control)
in isolated mitochondria (Darley-Usmar et al. 1983;
Kennaway et al. 1984). Other respiratory-chain activi-
ties were normal. Western blot analysis revealed low
levels of multiple subunits of complex III, and cyto-
chrome spectra showed severe reduction of cytochrome
b with normal levels of cytochrome aa3. Complex III
activity was normal in peripheral blood leukocytes,
transformed lymphocytes, and cultured skin fibroblasts
(Darley-Usmar et al. 1986). Exercise testing at this time
showed an early anaerobic threshold and severe reduc-
tion in maximal oxygen consumption (Elliot et al. 1989).
Evaluation of muscle bioenergetic capacity by [31P]–
magnetic resonance spectroscopy (MRS) revealed low
levels of phosphocreatine relative to inorganic phos-
phate, with slow recovery following exercise (Eleff et al.
1984). After treatment with menadione and ascorbate,
the patient showed improvement in clinical parameters,
as well as in the bioenergetic state of her skeletal muscle,
as documented by [31P]-MRS (Eleff et al. 1984; Argov
et al. 1986).
By age 19 years, the patient had clear evidence of
encephalopathy, with emotional lability, seizures, ab-
normal EEG, intermittent visual hallucinations, depres-
sion, and psychiatric problems. At age 23 years, a needle
muscle biopsy was performed, with informed consent,
during elective bilateral tubal ligation. Menadione had
to be discontinued because of its withdrawal by the FDA.
The following year, she developed increasing episodes of
encephalopathy, with poor balance, diplopia, confusion,
hallucinations, and occasional myoclonic twitches.
These continued over the next few years, accompanied
by nausea, vomiting, and complex partial seizures. She
suffered a left-sided stroke from which she recovered
completely. By age 31 years, emotional problems with
memory loss, dizziness, vomiting, and weight loss were
evident. Echocardiogram and retinal examination were
normal. Because of excessive menstrual bleeding, an elec-
tive hysterectomy was performed, and samples of uterus
were frozen for subsequent analysis. Over the past 2–3
years, the patient has been remarkably stable, with no
major encephalopathic episodes. Recently, she developed
ovarian cysts, which necessitated surgical resection.
These were identified as benign mucinous cystadenomas.
Samples of ovarian tissue and rectus abdominis muscle
were obtained at the same time, with informed consent,
and frozen for subsequent DNA analysis. These studies
were approved by our Institutional Review Board.
Fibroblast Culture
Cultured skin fibroblasts were grown in alpha MEM
(Gibco BRL) supplemented with penicillin (100 IU/ml),
streptomycin (100 mg/ml), and 10% fetal bovine serum.
Uridine (50 mg/ml) was added where indicated.
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Muscle Histochemistry and Immunocytochemistry
Skeletal muscle, obtained by open biopsy, was im-
mediately frozen in liquid nitrogen–cooled isopentane
and stored at 80C. Muscle sections (8 mm) were
stained for cytochrome c oxidase (COX), succinate de-
hydrogenase (SDH), and myofibrillar actomyosin ATP-
ase, as described elsewhere (Taanman et al. 1996). Fiber
type was determined by the ATPase activity at pH 9.4,
following preincubation at pH 4.5. RRFs were identified
with the modified Gomori trichrome stain or by in-
creased SDH activity. Immunocytochemistry was per-
formed as described elsewhere (Keightley et al. 1996;
Taanman et al. 1996), using a monoclonal antibody to
COX subunit I (COXI) and polyclonal antibodies to
subunit 1 of complex I (ND1, a kind gift from Dr. R.F.
Doolittle), holocomplex II (holoII, kindly provided by
Dr. B. Akrell), and to three subunits of complex III (the
Rieske protein, 13.4-kDa protein, and cytochrome b,
generously provided by Dr. L. Yu).
Isolation, Cloning, and Sequencing of mtDNA
DNA was isolated from tissues as described elsewhere
(Keightley et al. 1996). For hair roots, a modification of
a standard method (Bing and Bieber 1998) was used.
Briefly, a 1-cm portion containing the root was rinsed
in sterile deionized water. Cells were lysed overnight at
37C in 0.01 M Tris-Cl, pH 7.4, 0.01 M EDTA, 0.01
M NaCl, 1% SDS, and 0.15 mg/ml proteinase K and
DNA purified by organic extraction and ethanol precip-
itation (Sambrook et al. 1989). The cytochrome b gene
was amplified by PCR using a mismatched (italicized
nucleotides) forward primer 5′-AGGAGAATTCTTA-
GAAGAAAACCCCACAAAC-3′ and the reverse primer
5′-ATAGCGGCCGTTGATGGGTGAGTCAATAC-3′,
which bind to nt 14599–14629 and 16088–16060 of
mtDNA, respectively. Sequences are numbered accord-
ing to the L strand of the Cambridge reference sequence
(Anderson et al. 1981). The PCR reaction (75 ml) con-
tained 10 pmol of each primer, 10 mM Tris-Cl (pH8.3),
50 mM KCl, 1.5 mM MgSO4, 0.01% (w/v) gelatin, 160
mM dNTPs, and Taq polymerase. Reactions were cycled
32 times for 20 s at 94C, 30 s at 64C, and 60 s at
72C. Amplified products were purified from agarose
gels using Wizard PCR Preps (Promega), digested with
Sau3AI, and cloned by ligation into BamHI-digested
pBSII-SK (Stratagene). After transformation of Escher-
ichia coli XL-1 Blue (Stratagene) (Hanahan 1985), col-
onies were selected and plasmid DNA screened to iden-
tify clones representing each of the Sau3AI fragments
(mtDNA nt 14871–15061, 15062–15358, and 15359–
15592). The 5′ end of the cytochrome b gene was cloned
using the EcoRI site introduced by the mismatched for-
ward PCR primer (italicized bases in sequence above)
and a XhoI site at nt 14955; directional clones were
generated by digesting agarose purified PCR product
with EcoRI and XhoI and ligating the resulting 352-bp
fragment into pBSII-SK. The directional (EcoRI/XhoI)
clone and internal Sau3AI clones were sequenced from
plasmid DNA (both strands, on a minimum of two
clones each), using the Sequenase deaza-dGTP sequenc-
ing kit (USB). The 3′ end of the gene resisted cloning
and was therefore cycle sequenced (both strands) on the
full-length PCR product, using fluorescently labeled di-
deoxynucleotide terminators and an Applied Biosystems
373A automated sequencer.
Detection and Quantitation of the Cytochrome b
G15242A Mutation by PCR-RFLP
The G15242A mutation introduces an Eam1104I re-
striction site, which was used to develop a PCR-based
RFLP assay for mutation detection. A 769-bp fragment,
which spanned nt 14976–15744 of mtDNA and also
contained two wild-type Eam1104I sites (nt 15031 and
15451), was generated by PCR (50-ml reaction volume)
as above, except that (1) the forward primer was 5′-
GAATCATCCGCTACCTTCACGCC-3′ (nt 14976–
14998) and the reverse primer was 5′-AGGAGGTCTG-
CGGCTAGGAGTCA-3′ (nt 15744–15722) and (2) 30
mM dATP (or dCTP) was used instead of 160 mM. Re-
actions were cycled 24 times for 20 s at 94C, 30 s at
68C, and 60 s at 72C, followed by an additional cycle
(using a 2-min denaturation) in the presence of 5 mCi
(3,000 Ci/mmol) of [a32P]-dATP (or dCTP). Labeled
PCR products were digested with Eam1104I (Strata-
gene) and resolved by nondenaturing PAGE (6% poly-
acrylamide). Fragments of 420, 291, and 58 bp were
produced in wild-type mtDNA. In the mutant, the 420-
bp fragment was cleaved into fragments of 217 and 203
bp. The proportion of mutant mtDNA was quantitated
from the 420-, 217-, and 203-bp fragments, using a
phosphorimaging system and IMAGEQUANT software
(Molecular Dynamics), with local area background
subtraction.
Analysis of Microdissected Muscle Fibers
For single-muscle-fiber analysis, alternating 40- and
8-mm-thick serial sections of muscle were prepared. The
40-mm sections were stained immunocytochemically
with antisera to the Rieske protein of complex III and
placed in 50% ethanol. The 8-mm-thick flanking sections
were also stained immunocytochemically for the Rieske
protein, and these, which stained more intensely than
the 40-mm sections, were used as references for scoring
the adjacent 40-mm sections as complex III positive or
negative. Additional 8-mm flanking sections were stained
histochemically for SDH, to identify RRFs. Single fibers
were microdissected from the 40-mm sections using stain-
less steel microelectrodes and were prepared as described
elsewhere (Keightley et al. 1996). PCR-RFLP analysis
was conducted as described above, except that (1) 40
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pmol of each primer was used, (2) hot-start PCR was
used, and (3) reactions were cycled 30 times for 40 s at
95C, 40 s at 60C, and 40 s at 72C. Last-cycle labeling
(95C for 1 min, 60C for 45 s, and 72C for 2 min)
was performed on 35 ml of the PCR reaction, after ad-
dition of a further 15 pmol of each primer, 2 U of Taq
polymerase, and 10 mCi of [a32P]-dCTP (6,000 Ci/
mmol). PCR products were purified over Microspin S-
200 HR columns (Pharmacia), were vacuum dried, and
were subjected to RFLP analysis as described above. Sta-
tistical analysis usedWelsh’s alternative t test (Instat Pro-
gram, version 2.01).
Results
Histochemistry and Immunocytochemistry of Muscle
Sections
Previous studies of muscle from our patient had iden-
tified numerous RRFs, the complete absence of COX-
negative fibers, and deficient activity of complex III as-
sociated with multiple subunit deficiencies (Darley-
Usmar et al. 1983; Kennaway et al. 1984). We therefore
investigated whether we could use an immunocytochem-
ical method to confirm an isolated complex III deficiency
in serial sections of muscle (fig. 1). The results showed
that individual type I fibers (black arrows) or type II
fibers (white arrows) could be identified as complex III
positive (filled-in arrows) or negative (outlined arrows),
on the basis of their punctate (mitochondrial) intermy-
ofibrillar immunoreactivity toward antisera against
complex III subunits (cytochrome b, the Rieske protein,
and the 13.4-kDa protein), compared with their im-
munoreactivity to antibodies against complex I (NDI),
complex II (holoII), or complex IV (COXI). The heavier
staining with antisera against the Rieske protein, com-
pared with that of antisera against cytochrome b or the
13.4-kDa protein, reflects the stronger immunoreactivity
of the Rieske protein antiserum; the heavier labeling in
subsarcolemmal regions of RRFs appeared to be pre-
dominantly nonspecific. These results not only con-
firmed the specificity of the complex III deficiency but,
additionally, identified a mosaic of complex III–positive
and –negative type I and type II fibers, suggesting a mu-
tation in the mtDNA-encoded cytochrome b gene in this
patient.
Detection of a Stop-Codon Mutation in the
Cytochrome b Gene
In view of the severe and specific deficiency of complex
III in this patient and the mosaic of complex III–positive
and –negative muscle fibers, we next sequenced the cy-
tochrome b gene in muscle. This identified a GrA tran-
sition at nt 15242 (G15242A), which converts a glycine
codon to a stop codon (G166X; fig. 2; GenBank acces-
sion number AF254896). This change, which has not
been reported previously, results in the loss of 215 amino
acids, representing 57% of the protein at the C terminus
of cytochrome b. The only other change in the patient’s
cytochrome b gene, compared with the Cambridge ref-
erence sequence, was the reported A15326G polymor-
phism (Andreu et al. 1999b). We also ruled out the pres-
ence of the common MELAS A3243G and MERRF
A8344G mtDNA mutations (data not shown).
Quantitation of the Cytochrome b Stop-Codon
Mutation in Different Tissues
The G15242A mutation creates an Eam1104I restric-
tion site, which allowed us to develop a simple PCR-
RFLP method for detection and quantitation of the pro-
portion of mutant mtDNA. PCR-RFLP analysis of
skeletal muscle and blood from the patient and her rel-
atives (fig. 3) revealed very high levels of the G15242A
mutation (87%) in the patient’s skeletal muscle and very
low, but detectable, levels in blood (0.7%). Very faint
mutant bands suggested the presence of trace amounts
of the mutation (!0.2%) in blood from the patient’s
sister, but this was at the limit of detection. Themutation
was not detected in her mother’s blood nor in 180 con-
trol samples (58 blood and 28 muscle samples from con-
trols and patients with a variety of neuromuscular dis-
eases). Mutation analysis in other tissues from the
patient (fig. 3) showed very high levels of mutant
mtDNA in rectus abdominis muscle (92%), high levels
in uterus (61%), and low levels in ovarian tissue, both
from the cyst itself and from surrounding tissue that
contained cyst contamination (4%–5%). The propor-
tion of mutant mtDNA in fibroblasts varied with the
length of time in culture, increasing steadily from 29%
to 75% during the course of 10 population doublings
over a period of 7 weeks (fig. 3). A similar trend was
seen regardless of whether the culture medium was sup-
plemented with uridine, which is essential for the growth
of respiratory-deficient cells (King and Attardi 1989)
(data not shown). In a series of 22 individual hair roots
from the patient, the G15242A mutation was detected
in 8; the proportion of the mutation varied widely, rang-
ing from !0.4% to 66% (mean 4.6%).
Proportion of the Cytochrome b G15242A Mutation in
Single Muscle Fibers
Individual fibers were classified as complex III positive
or negative on the basis of immunostaining of flanking
sections with antisera against the Rieske protein of com-
plex III (see fig. 1) then analyzed by PCR-RFLP. The
results (fig. 4) showed a significant correlation between
the proportion of the G15242A mutation in complex
III–positive fibers ( ; mean  SD), com-32% 29%
pared with that in complex III–negative fibers
( ) ( ), and especially in complex66% 26% P ! .0001
III–negative RRFs ( ) ( ). The cor-89% 8% P ! .0001
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Figure 1 Histochemistry and immunocytochemistry of serial sections of skeletal muscle from the patient. Type I (heavy) and type II (light)
fibers are distinguished on the basis of their intensity of staining for ATPase, COX, and SDH activities (top). The black arrows (two outlined
and one filled in), most easily seen with the SDH reaction, identify three type I fibers, one of which is an RRF (*). Two other RRFs (*) are
also identified. The white arrows (one outlined and one filled in) identify two type II fibers. The center panel shows immunoreactivity with
antibodies to ND1, COXI, and holoII. Similar intensity of staining is seen in the three type I fibers and in the two type II fibers. The bottom
panels show immunoreactivity with antibodies to three subunits of complex III (cytochrome b, the Rieske protein, and the 13.4-kDa protein).
In these cases, a clear difference can be seen between two of the type I fibers (outlined black arrows), which react poorly with all complex III
antibodies, compared with the third type I fiber (filled-in black arrow). Similarly, one of the type II fibers (outlined white arrow) reacts poorly
with all three complex III antibodies, compared with the other type II fiber (filled-in white arrow).
responding median values were 33%, 76%, and 89%,
respectively. The immunopositive reaction in 3 of 33
fibers with 170% of the G15242A mutation and the
immunonegative reaction in 6 of 31 fibers with !50%
of the mutation most likely reflect the fact that the im-
munostaining was performed in 8-mm sections imme-
diately adjacent to the 40-mm sections used for mutation
analysis, and there may be some variability in the dis-
tribution of the mutant mtDNA, even between adjacent
sections. Another possibility is that there is not an exact
correlation between the levels of Rieske protein and the
proportion of mutant mtDNA, since deficiency of the
Rieske protein is a secondary phenomenon, reflecting
lack of assembly or increased degradation of nuclear-
encoded subunits of complex III, as a consequence of
deficient functional cytochrome b.
Discussion
Our patient, who was diagnosed many years ago with
complex III deficiency, has been of particular interest
because of her well-documented clinical and bioenergetic
response to treatment with menadione and ascorbate,
which were proposed to bypass the defect of electron
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Figure 2 Identification of a nonsense mutation in the cytochrome b gene. Autoradiogram of a DNA sequencing gel spanning nt
15230–15247 (5′r3′) of human mtDNA, showing sequence from a control (left panel) and the patient’s muscle (right panel). The GrA transition
in the patient’s sequence (nt 15242; arrow) converts a glycine codon (GGA) to a stop codon (AGA).
transport between ubiquinol and cytochrome c (Eleff et
al. 1984; Argov et al. 1986). Although the original stud-
ies of muscle—including enzymatic, spectral, and west-
ern blot analyses—all indicated a severe and specific de-
ficiency of complex III, the molecular basis was not
known. Complex III of the mitochondrial respiratory-
chain transfers electrons from ubiquinol to cytochrome
c, coupled with the transfer of electrons across the mi-
tochondrial inner membrane. It contains three redox-
active centers (cytochrome b, cytochrome c1, and the
Rieske FeS protein) and is composed of 11 polypeptide
subunits, 1 of which (cytochrome b) is encoded by
mtDNA. Disorders of complex III are relatively rare,
comprising only 7% of patients with respiratory-chain
disorders in a recent series of 157 patients (von Kleist-
Retzow et al. 1998). A deficiency of complex III could
be of either nuclear or mitochondrial origin. The im-
munocytochemical studies of skeletal muscle, presented
here, confirmed the specificity of the complex III defi-
ciency in our patient and, more importantly, identified
a mosaic of complex III–immunopositive and –immu-
nonegative fibers, strongly suggesting a mutation of
mtDNA. The ability to utilize antisera to the Rieske or
13.4-kDa proteins for these experiments presumably re-
flects a lack of assembly or increased degradation of
nuclear-encoded subunits of complex III in the absence
of a functional cytochrome b, as also occurs in yeast
(Sen and Beattie 1985). A mosaic of COX-positive and
-negative fibers is readily recognized histochemically in
patients with COX deficiency associated with mutations
of mtDNA (Keightley et al. 1996; DiMauro and Bonilla
1997). In contrast, no histochemical stain is available to
document similar mosaicism in patients with complex I
or complex III deficiency. Our results suggest that im-
munocytochemistry, using serial sections of muscle and
specific antibodies to complex I or complex III, may be
a valuable diagnostic technique to localize a specific res-
piratory-chain deficiency, especially in small muscle sam-
ples. This technique can also provide direction for mo-
lecular analyses focused on either the nuclear or
mitochondrial genome. Moreover, for mutations of
mtDNA, it can be used to correlate the proportion of
mutant mtDNA with the phenotype in single muscle
fibers, a critical step in establishing the pathogenicity of
an mtDNA mutation, as has been demonstrated here.
The G15242A mutation in our patient is almost cer-
tainly pathogenic, resulting in a protein truncated by
150% at the C terminus. Additional evidence for path-
ogenicity is as follows: (1) the mutation is heteroplasmic
and occurs at higher proportions in affected tissue (mus-
cle) than in unaffected tissue (blood); (2) it has not been
described elsewhere and was not identified in control
samples; (3) the mutation is consistent with the bio-
chemical and immunocytochemical phenotype that in-
dicated isolated complex III deficiency (furthermore, the
pattern of subunit deficiencies, documented elsewhere
in western blot analyses, included core proteins 1 and
2 and the Rieske protein, with sparing of cytochrome
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Figure 3 Distribution and quantitation of the cytochrome b G15242A mutation in different tissues. MtDNA was amplified by PCR,
with last-cycle labeling, to generate a 769-bp fragment, which was digested with Eam 1104I, and fragments were separated by nondenaturing
polyacrylamide electrophoresis (6%). In wild-type mtDNA, fragments of 420, 291, and 58 bp were produced (the last is not shown). In mutant
mtDNA, the 420-bp fragment was cleaved into products of 217 and 203 bp (*). Cultured skin fibroblasts at passage 5 (P5) were compared
with those at passage 10 (P10). Also shown are three representative hair roots. The proportion of the G15242A mutation in each sample is
indicated. ND p not detected; v.l. p vastus lateralis; r.a. p rectus abdominis.
c1, a pattern identical to that seen in yeast mutants de-
ficient in cytochrome b [Sen and Beattie 1985]); and (4)
there is a genotype:phenotype correlation in individual
muscle fibers, with complex III–immunodeficient fibers
having a significantly higher proportion of mutant
mtDNA than complex III–immunopositive fibers.
The G15242Amutation in our patient was the second
pathogenic cytochrome b mutation to have been iden-
tified (Dumoulin et al. 1996; Kennaway et al. 1998).
Since then, 12 additional patients with cytochrome b
mutations have been described (table 1). Remarkably,
five of these also had stop-codon mutations, and one
other had a 4-bp deletion that also led to premature
termination of translation. Many of the others had mu-
tations within or close to the ubiquinone-binding sites
of cytochrome b (Iwata et al. 1998; Andreu et al.
1999c), suggesting that most, if not all, of the cyto-
chrome b mutations are likely to have a severe effect
on mitochondrial energy production.
The phenotypes of the 14 patients with cytochrome
b mutations are surprisingly similar, 10/14 presenting
with isolated exercise intolerance and lactic acidosis,
sometimes accompanied bymyoglobinuria (4/14).None
had ophthalmoplegia. In at least nine patients, including
ours, RRFs were identified in muscle. RRFs are com-
monly found in patients who have major rearrange-
ments of mtDNA or mutations of mtDNA-encoded
tRNA genes and have also been described in at least
three patients with mutations of mtDNA-encoded COX
genes (Keightley et al. 1996; Comi et al. 1998; Clark
et al. 1999) (MIM 516050.0003, MIM 516030, and
MIM 516040, respectively). However, they are not nor-
mally found in patients with mutations of other protein-
encoding genes, such as those in ND1 (MIM 516000),
ND5 (MIM 516005), or ND6 (MIM 516006), com-
monly associated with LHON, or the T8993Gmutation
in the A6 gene associated with Leigh syndrome or neu-
rogenic muscle weakness, ataxia, and retinitis pigmen-
tosa (NARP [MIM 551500]). The factors that trigger
the proliferation of mitochondria in some but not other
disorders of mtDNA protein-encoding genes are not
known. However, our results and the above data in-
dicate that the presence of RRFs does not necessarily
reflect a generalized defect of mitochondrial protein syn-
thesis, as previously thought, but more likely represents
a severe energy deficit in cells with high levels of mutant
mtDNA.
The consistency of phenotype in most patients with
mutations in the cytochrome b gene contrasts with other
patients with complex III deficiency, in whom the age
at onset and clinical manifestations vary widely; in
many cases, this may reflect mutations in nuclear- rather
than in mtDNA-encoded genes (Mourmans et al. 1997).
There is a similar contrast between the majority of pa-
tients with cytochrome b mutations and most patients
with mutations of mtDNA-encoded tRNA genes in
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Figure 4 Proportion of the cytochrome b G15242A mutation
in single muscle fibers. Alternating 40- and 8-mm-thick serial sections
of muscle were obtained. The 40-mm sections and flanking 8-mm sec-
tions were stained immunocytochemically for the Rieske protein of
complex III and were scored as complex III positive or complex III
negative on the basis of the more intense staining of the 8-mm sections.
Additional 8-mm flanking sections were stained histochemically for
SDH, to identify RRFs. The 40-mm sections were microdissected and
subjected to PCR-RFLP analysis. The median proportion of mutant
mtDNA in each fiber type is indicated by a horizontal line. The mean
 SD is shown below. The differences between immunopositive and
immunonegative non-RRFs (columns 1 and 2), and between immu-
nopositive and immunonegative RRFs (columns 1 and 3), were highly
significant ( ).P ! .0001
which the variability of clinical manifestations is enor-
mous. Also in contrast to patients with tRNA muta-
tions, which are frequently maternally inherited, all of
the patients with cytochrome b mutations, with the pos-
sible exception of ours, have been sporadic cases, sug-
gesting that the cytochrome b mutation, if present in
the maternal germ line, may frequently be lethal during
early fetal development. Mutations in other mtDNA
protein-encoding genes, such as those in the A6 gene
associated with Leigh syndrome or NARP, or the mu-
tations in complex I genes commonly associated with
LHON, however, are almost always maternally inher-
ited. The fact that the LHON mutations are usually
homoplasmic, are not associated with RRFs, and are
maternally inherited suggests that they may have a less
severe effect on ATP synthesis than the mutations in the
cytochrome b gene, discussed above. Studies in trans-
mitochondrial cell lines should help answer this
question.
Our patient differs from most other patients with cy-
tochrome b mutations in two important respects. First,
although her presentation was dominated by severe ex-
ercise intolerance and lactic acidosis between the ages
of 9 and 19 years, she did have seizures from her early
teenage years, and she has developed significant en-
cephalopathy over the last 15 years. This raises the pos-
sibility that, given more time, some of the other patients
may also progress to a more severe phenotype. One
other patient with a cytochrome b mutation had a pre-
dominantly neurological presentation, described as ju-
venile Parkinson/MELAS overlap syndrome (patient 5,
table 1), and two others had severe hypertrophic car-
diomyopathy (patients 11 and 14). These three patients
also had an earlier age at onset and more severe pre-
sentation, compared with many other patients. Notably,
at least two of them had detectable levels of mutation
in blood and/or fibroblasts.
The second difference between our patient and most
of the other cases concerns the origin and tissue distri-
bution of the mutation. In the patients with an isolated
skeletal myopathy, the mutant mtDNA was absent in
blood and/or fibroblasts in all cases examined. This is
consistent with the restriction of the clinical phenotype
to skeletal muscle, the spontaneous occurrence of these
mutations, and the likelihood that they would not be
transmitted to the patients’ offspring (Griggs and Kar-
pati 1999). The highly skewed distribution of the mu-
tation between blood or fibroblasts, compared with
muscle, and the restriction of the clinical phenotype to
muscle, have led to the suggestion that the mutation in
these patients may have arisen in muscle progenitor
cells, after differentiation of the primary germ layers
(Andreu et al. 1999c). However, another possibility is
the occurrence of a sporadic mutation early during em-
bryogenesis or in the maternal germ line, with a highly
skewed distribution in tissues of the patient, arising as
a result of either mitotic segregation or selection against
the mutation by some unknown mechanism in most
tissues. Certainly, the absence of the mtDNA mutation
in blood and fibroblasts does not preclude its presence
in a variety of other tissues, as illustrated by the patient
with a heteroplasmic tRNALeu(CUN) mutation who had
sensorineural deafness and retinopathy in addition to a
severe skeletal myopathy (Fu et al. 1996). In our patient,
the G15242A mutation was relatively widely distrib-
uted, with very low levels in blood, low levels in ovarian
tissue, and moderate to high levels in uterus and cul-
tured skin fibroblasts. More importantly, the mutation
was also present in hair roots. In contrast to all other
tissues examined, which are of mesodermal origin, hair
roots are derived from primitive ectoderm, indicating
that the mutation in our patient must have arisen very
early in embryogenesis, before separation of the primary
germ layers, or in maternal germ line cells. Analysis of
blood from the patient’s mother and sister did not dif-
ferentiate between these two possibilities.
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Table 1
Summary of Patients with Mutations in the mtDNA-encoded Cytochrome b Gene
Patient Sex/Age
Age at
Onset
(years) Phenotype
RRF/
Lactic
Acidosis
Cytochrome
b Mutation
Amino
Acid
Change
%
Mutation
in Muscle
Mutation
Present in
Blood/
Fibroblasts Reference
1a F/34 y 9 EI, LE / G15242A G166X 87 / Kennaway et al. (1998)
2 M/25 y 10 EI, P / G15615A G290D 80 /NA Dumoulin et al. (1996)
3 F/38 y 25 EI, W / G15762A G339E 85 /NA Andreu et al. (1998)
4 F/27 y 12 EI, W, M / G15059A G105Xb 63 /NA Andreu et al. (1999a)
5 M/20 y 6 JP/MELAS / 14787del4 Del14fs/tr49 195 / DeCoo et al. (1999)
6 M/43 y 30 EI, W, M / 15498del24 Del251-258 50 / Andreu et al. (1999c)
7 F/52 y Child EI, W / G14846A G34S 85 / Andreu et al. (1999c)
8 F/38 y Child EI / G15168A W141X 70 /NA Andreu et al. (1999c)
9 M/32 y Child EI / G15084A W113X 87 /NA Andreu et al. (1999c)
10 M/51 y Child EI, M NA/ G15723A W326X 87 NA/NA Andreu et al. (1999c)
11 F/8 y 3 SHC NA/ G15243A G166E 90c NA/ Valnot et al. (1999)
12 M/18 y 8 EI, M / G15150A W135X 60 / Legros et al. (1999)d
13 M/51 y Teen EI, W / T15197C S151P 70 / Legros et al. (1999)d
14 F/4 w Infant SHC NA/NA G15498A G251D NA NA/NA Andreu et al. (2000)
NOTE.—EI p exercise intolerance; W p weakness; M p myoglobinuria; SHC p severe hypertrophic cardiomyopathy; JP p juvenile
Parkinsons; P p muscle pain; LE p late-onset encephalopathy; y p years; w p weeks; Del p deletion; fs p frameshift; tr p termination;
NA p not available or not analyzed.
a Present case.
b Corrected from Andreu et al. 1999b.
c Cardiac muscle.
d Also includes data from A. Lombes, personal communication.
Although the average proportion of the G15242A
mutation in hair roots from our patient was only 4.6%,
the finding of much higher proportions in some indi-
vidual hair roots (up to 66%) than in blood (0.7%)
suggests that hair roots may provide a more sensitive
method for detecting heteroplasmic mtDNAmutations,
as has been suggested elsewhere, in studies of a family
harboring a mitochondrial tRNAGlu mutation (MIM
590025) (Hao et al. 1995). Examination of mutant
mtDNA in patients with MELAS, MERRF, and NARP
showed a good correlation between the percentage of
mutant mtDNA in blood, compared withmuscle, buccal
cells, and hair roots (Wong and Lam 1997). These au-
thors stress that pooling of hair cells minimizes the dis-
crepancies obtained with single-follicle analysis. How-
ever, in patients such as ours, in whom the mutant
mtDNA in blood is barely detectable, the wide varia-
bility in hair roots suggests that measurement of mutant
mtDNA in individual follicles may be more sensitive for
detecting asymptomatic carriers of the mutation in
whom the level of mutant mtDNA in pooled follicles
may be at the limit of detection.
The marked variability in the distribution of mutant
mtDNA between different tissues (e.g., muscle and
blood) and even within individual tissues (e.g., muscle
fibers or hair roots) presumably reflects replicative seg-
regation. In cultured skin fibroblasts, the increasing pro-
portion of the G15242A mutation with increasing time
in culture is harder to understand, since there is no
obvious selective advantage to cells or mitochondria
harboring high levels of a stop-codon mutation. How-
ever, in fibroblast cultures from one patient with intra-
cellular mtDNA triplasmy, the proportion of one mu-
tation (A5656G) was also found to increase with
increasing time in culture (Bidooki et al. 1997). More-
over, increasing proportions of mutant mtDNA have
been reported over time in vivo in patients harboring
pathogenic mtDNA deletions (Larsson et al. 1990) or
point mutations (Weber et al. 1997). In one family with
a heteroplasmic tRNAGlu mutation, the proportion of
mutant mtDNA (studied in individual hair roots) tended
to increase in successive generations (Hao et al. 1995).
Finally, in transmitochondrial cell lines harboring the
MELAS 3243 mutation, different levels of heteroplasmy
were found to either increase, decrease, or remain stable
over time in culture; although the mechanisms respon-
sible for these changes are not understood, they appear
to depend on the nuclear background of the cells
(Yoneda et al. 1992; Dunbar et al. 1995).
The presence of the G15242A mutation in hair roots
from our patient suggests that the mutation may also
be present in the CNS, which is also derived from prim-
itive ectoderm. This would be consistent with her neu-
rological symptoms. In this regard, it should be noted
that the cytochrome b microdeletion in the patient with
a more severe neurological disorder described as juve-
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nile Parkinson/MELAS overlap syndrome (table 1) was
also present in hair roots. The occurrence of hetero-
plasmic cytochrome b mutations in hair roots from the
two patients with encephalopathic manifestations sug-
gests that hair-root analysis can provide a useful reflec-
tion of the tissue distribution of the mutation, the po-
tential clinical phenotype, and, perhaps, the risk of
transmitting the mutation to their offspring. These ques-
tions can only be answered by further long-term studies
of additional patients.
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